Durham-based Argos Therapeutics is expanding its physical footprint by leasing 40,000 square feet of space at North Carolina State University’s Centennial Campus.

The space is designated for manufacturing of immunotherapies being developed by Argos.

Some 70 new jobs are expected to be created.

The space is in the Center for Technology & Innovation.

Argos is seeking approval for a treatment called rocapuldencel-T which the company hopes will be approved as a treatment for metastatic renal cell carcinoma (mRCC).

“Securing a lease for the CTI facility is a critical step on our path towards becoming a fully-integrated commercial-stage biotechnology company,” said Jeff Abbey, president and chief executive officer of Argos. “Our two-stage manufacturing strategy positions us to employ an established and proven-effective manual manufacturing process at CTI with the capacity to support approximately 1,800 patients per year at launch, with expansion capacity to 2,400 patients per year, pending regulatory approval.

“This strategy optimizes capital utilization as we prepare for a BLA submission for rocapuldencel-T and also allows us to assess early commercial uptake and better project capacity requirements for our planned 125,000 square foot Centerpoint facility in Durham, NC, which can be designed to accommodate our automated manufacturing process.”